India’s devastating Covid-19 crisis is threatening operations at some of its biggest ports, raising concerns. The action could trigger shipping delays that reverberate through global supply chains.
The situation may echo global trade disruptions seen last year after virus restrictions slowed shipments into China. While India accounts for only fraction of the global trade that China does, any delays in offloading vessels and releasing them to their next destination could create supply chain bottlenecks.
India has 21.9 million tons of cargoes scheduled to arrive during May-June’21 but with labor shortages and force majeure at some ports, many of the vessels could see discharge delays. That may have a knock-on effect on scheduled loadings at the exporting countries.
In the global shipping scenario, India’s surging second wave of COVID-19 infections has dealt a hard blow to the global shipping industry as India is one of the largest suppliers of crew. The sudden surge in coronavirus infections and a shortage of vaccines have left ship workers high and dry.
It has sparked travel curbs and restrictions on Indian crews, sending shipping firms scrambling to find replacements.
Global ports are now slamming doors on Indian crew and vessels. Companies are insisting on vaccinated workers and seafarers, spelling bad news for an already stretched maritime sector.
With a growing number of seaports and airports closing their doors to seafarers to and from India, shipping companies say it’s leading to bottlenecks in crew changes. Several companies are temporarily tapping seafarers from other nations to replace Indians scheduled to board ships.
Reference:
https://www.dw.com/en/india-covid-seafarers-shipping/a-57529998
https://economictimes.indiatimes.com/industry/transportation/shipping-/-transport/india-covid-crisis-hits-work-at-its-biggest-ports-as-risk-to-trade-grows/articleshow/82633023.cms
Global shipping costs have climbed to $4,000–$4,500 in October from $2,000–$2,500 in February 2026. Freight rates, which had eased through much of 2025 and early 2026 as the demand-supply balance improved, have rebounded sharply in recent months. The increase has brought shipping costs back into focus for businesses dependent on international cargo movement.
The U.S. Food and Drug Administration (FDA) has finalized guidance outlining how manufacturers should report post-approval manufacturing changes for biosimilar and interchangeable biosimilar products. The guidance provides greater regulatory clarity on changes involving production processes, manufacturing sites, analytical methods, raw materials, and process controls. It aims to ensure product quality while reducing unnecessary regulatory burden.
A significant uptick in M&A activity in the biosimilars sector is being driven by FDA regulatory reforms, a maturing patent litigation framework and a looming patent cliff — $200 billion of branded products are facing patent expiration by 2030.
The Drewry World Container Index edged lower this week as falling Asia-Europe rates outweighed firmer pricing on the Transpacific, with carriers preparing another round of blank sailings ahead of China’s Golden Week holiday.
On 14 July 2026, the European Parliamentary Research Service (EPRS) published a comprehensive briefing on PFAS (per- and polyfluoroalkyl substances), also known as ‘forever chemicals’. The document is intended to serve as a technical basis for MEPs in their upcoming political decisions on PFAS regulation and summarises the current state of scientific knowledge, regulation and procedures.
Following a series of typhoon disruptions in East China during the month of August, major ports including Shanghai and Ningbo continue to experience congestion and operational recovery challenges. Industry reports indicate that vessel schedules, yard operations, and equipment circulation remain affected as terminals work through accumulated backlogs from successive storm events.
Under REACH Annex XVII Entry 78, the EU has banned the placing on the market of synthetic polymer microparticles (SPMs) unless a specific derogation applies. Derogations exist for essential uses such as:
As a result of the amendment of the CLP Regulation (Regulation (EC) No 1272/2008 on the classification, labelling and packaging of substances and mixtures), new hazard classes have entered into force.
In a converging policy shift on both sides of the Atlantic, European regulators this week published a roadmap toward fully replacing animal testing for chemical safety assessments, while the US Environmental Protection Agency issued a rare update to its list of alternative test methods.